Article Text

PDF

Graves’ disease associated with exophthalmos, cerebral ventricular dilatation and accelerated growth
  1. Osamu Arisakaa,
  2. Atsuto Hosakaa,
  3. Hajime Araib,
  4. Sachi Fujiwaraa,
  5. Rieko Tadokoroa,
  6. Keijiro Yabutaa
  1. aJuntendo University School of Medicine, Tokyo, Japan: Department of Pediatrics, bDepartment of Neurosurgery
  1. Dr O Arisaka, Department of Pediatrics, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113, Japan.

Abstract

A report is presented of a girl with Graves’ disease, which was diagnosed at the age of 1.7 years. The mother had no thyroid disease. The patient developed signs of hyperthyroidism shortly before her first birthday, and the most prominent manifestations were accelerated skeletal maturation and linear growth, and dilatation of the brain ventricles. The latter manifestation, which has not been reported previously, was reversible upon normalisation of thyroid function with antithyroid treatment for three years.

  • Graves’ disease
  • reversible ventriculomegaly
  • growth acceleration.

Statistics from Altmetric.com

Hyperthyroidism during childhood is usually caused by Graves’ disease. Apart from the transient neonatal cases that develop in infants born to mothers with active Graves’ disease, the disease occurs infrequently in preschool children and rarely may begin in infancy.1 2

We describe the four year clinical course of a patient with Graves’ disease that was diagnosed at 1.7 years of age, although the disease had probably developed in late infancy. There were typical clinical signs of hyperthyroidism, but the patient’s growth and development were most affected.

Case report

A girl aged 1.7 years was referred because of bilateral exophthalmos (fig 1). She had been born normally (weight 2980 g) as the first child to a healthy mother. The family history did not suggest thyroid disease or other autoimmune diseases. The patient was 88.2 (+2.5 SD) cm tall, with a body weight of 12 kg and a head circumference of 46.5 (+0.2 SD) cm. She presented with restlessness, sweating, mild thyromegaly, tachycardia (130/min), and a systolic murmur (Levine 3/6). She had upper eyelid retraction and infrequent blinking. The anterior fontanelle was closed, and there was no frontal bossing or craniosynostosis. She had increased deep tendon reflexes, and her optic fundi were normal.

Figure 1

Signs of exophthalmos in the patient. Left, patient at 8 months showing no exophthalmos. Right, patient at 1.2 years when prominent eyes (mild exophthalmos) are evident.

Further questioning revealed that these signs had developed shortly before 1 year of age. However, her milestones of motor and mental development up to the time of presentation had been normal except for linear growth acceleration with advanced skeletal development (4.5 years by TW2 method for Japanese children3) (fig 2). Also, a photograph taken at the age of 8 months revealed no exophthalmos (fig 1).

Figure 2

Patient’s growth curves and serial measurements of bone age. Radiograph of hand shows the bone age (BA) at diagnosis (CA=chronological age). Accelerated linear growth and advanced bone age became less remarkable after initiation of antithyroid treatment.

Thyroid function tests including immunological tests and biochemical tests are shown in table 1. The mother was euthyroid and had no detectable antithyroid antibodies including antimicrosomal antibody and thyrotrophin binding inhibitory immunoglobulins (TBII). Cardiomegaly (cardiothoracic ratio 60%) was recognised in a chest xray film, and mitral valve regurgitation was detected by colour Doppler echocardiography. Brain computed tomography had shown dilatation of the ventricular system (fig 3). This scan had been carried out at the referred hospital to rule out retro-orbital tumours.

Table 1

Laboratory data of the patient at admission

Figure 3

Serial examinations by brain computed tomography. Dilated lateral ventricles (bottom) and fourth ventricles (top) regressed after antithyroid treatment. Left: 1.7 years (at diagnosis of Graves’ disease); centre: 2.3 years; right: 4.5 years.

A diagnosis of Graves’ disease was made and treatment was started with antithyroid drug (methimazole 10 mg daily) and a β-adrenergic blocker (propranolol 5 mg daily). Thyroid function became normal in several months. Propranolol was then withdrawn and the dose of methimazole was reduced (5–2.5 mg), but maintained thereafter. The systolic heart murmur and exophthalmos (fig 1) remained for two to three years and ventricular dilatation regressed over a four year period (fig 3).

Antithyroid treatment was stopped at the age of 4.5 years, when thyroid function (thyroxine 93.9 nmol/l; triiodothyronine 2.15 nmol/l; thyroid stimulating hormone 2.27 mU/l; TBII 2.9%) and the result of a triiodothyronine suppression test appeared normal. During the treatment, there were no complications.

On review at 5 years of age, the patient was within the normal ranges for social, motor, and communicative development. Her growth curve with skeletal ages are shown in fig 2. At present, sexual development is Tanner stage I.

Discussion

Occasionally, neonatal hyperthyroidism does not remit and persists into childhood. Such patients may have a family history of hyperthyroidism, although circulating thyroid antibodies are absent.2 5 6 It has recently been established that children with this disorder have a mutation of the thyroid stimulating hormone receptor gene.7 In the present patient, the autoimmune pathogenetic mechanism of adult Graves’ disease was operating, because circulating thyroid stimulating hormone antibody was evident at the time of diagnosis and its activity decreased as the disease ameliorated.

As Graves’ disease progresses insidiously, it is difficult to know when the hyperthyroidism in the present patient developed. It may not have occurred until mid-infancy, because exophthalmos, clinical signs of hyperthyroidism, and growth acceleration had not been evident until then. Furthermore, skull abnormalities, such as frontal bossing, craniosynostosis, and microcephalus, which are evidence of abnormal membranous bone maturation due to the early effect of thyroid hormone,8-10 were not recognised in the present case. Therefore we suspect that the disease developed at a later stage of infancy.

In our patient, there were various typical manifestations of hyperthyroidism, some of which are usually seen in older patients. The most prominent manifestation was accelerated skeletal maturation and growth, although these phenomena have been reported to occur commonly in young children with Graves’ disease.1 2 The raised serum osteocalcin level and the increased urinary calcium/creatinine ratio would have indicated a bone metabolic status representative of increased bone turnover due to excess thyroid hormone.11

The ventriculomegaly in the present case was an unexpected finding. This feature has been documented in only one report of twins with congenital hyperthyroidism associated with ventriculomegaly and cerebral atrophy revealed by computed tomography; however, these abnormalities associated with mental delay were thought to be caused by brain maldevelopment in utero due to maternal hyperthyroidism.12 Pseudotumour cerebri (benign intracranial hypertension) occurs in association with a variety of endocrine and metabolic disorders including hypothroidism and hyperthyroidism, but cranial computed tomography usually shows normal sized ventricles, and funduscopic examination shows papilloedema on.13-15 The ventriculomegaly in our patient was reversible with normalisation of thyroid function. Alterations in cerebrospinal fluid absorption and/or production, or abnormality of cerebral blood flow due to hyperthyroidism may have been responsible for this brain manifestation. Fortunately, this involvement did not appear to affect the psychomotor development of the patient.

The persistent form of Graves’ disease which develops in infancy, as described here, is very rare, but early recognition and antithyroid treatment are critical because a delay in the diagnosis of such young patients can have a marked effect on growth and development.

Acknowledgments

This work was presented at the 29th Annual Meeting of the Japanese Society for Pediatric Endocrinology, Okayama, Japan, November 1995.

References

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.